Skip to main content

Table 1 Clinical characteristics, laboratory and imaging findings of the 35 patients at admission

From: Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study

 

Total (n = 35)

With HCQ/CQ (n = 14)

Without HCQ/CQ (n = 21)

P value

Age

62.20 ± 11.88

61.00 ± 13.00

63.00 ± 11.33

0.633

Male

23

10

13

0.721

Disease duration (days)

13.00 ± 7.24

13.00 ± 7.14

13.00 ± 7.49

1.000

Clinical manifestation at beginning

 Fever

27

10

17

0.685

 Fatigue

25

11

14

0.704

 Cough

26

12

14

0.262

 Diarrhea

8

3

5

1.000

 Myalgia/arthralgia

10

7

3

0.053

 Fever at admission

7

2

5

0.676

Comorbidities

 Hypertension

13

7

6

0.199

 Diabetes mellites

5

2

3

1.000

 Carcinomaa

5

3

2

0.369

 Stroke

1

1

0

0.400

 Coronary artery disease

2

1

1

1.000

 Lung diseaseb

6

1

5

0.366

 HBV infection

7

3

4

1.000

Disease severity status

 General

19

7

12

0.678

 Severe/critical

16

7

9

 

CURB-65 score

 0

15

6

9

1.000

 1–5

20

8

12

 

Laboratory results

 WBC (× 109/L)

6.13 ± 2.45

6.27 ± 2.96

6.05 ± 2.12

0.801

 Neu (× 109/L)

4.33 ± 2.38

4.68 ± 2.88

4.10 ± 2.01

0.490

 Lym (× 109/L)

1.08 ± 0.52

1.05 ± 0.56

1.09 ± 0.50

0.828

 Neu/Lym

5.27 ± 4.31

6.16 ± 5.13

4.69 ± 3.67

0.329

 Hb (g/L)

123.17 ± 18.43

126.14 ± 19.22

121.19 ± 18.08

0.444

 PLT (× 109/L)

266.37 ± 111.96

283.86 ± 110.58

254.71 ± 114.04

0.459

 ALT (U/L)

33.14 ± 28.69

27.00 ± 21.31

37.24 ± 32.56

0.308

 AST (U/L)

32.11 ± 20.96

27.00 ± 13.72

35.52 ± 24.37

0.244

 Alb (g/L)

33.26 ± 5.60

31.94 ± 6.51

34.14 ± 4.87

0.260

 LDH (U/L)

282.69 ± 126.59

310.00 ± 130.40

264.48 ± 123.78

0.304

eGFR (mL/min/1.73 m2)

89.33 ± 15.88

86.17 ± 12.15

91.43 ± 17.92

0.345

 > 90 mL/min/1.73 m2

20

7

13

0.486

 ≤ 90 mL/min/1.73 m2

15

7

8

 

Fibrinogen (g/L)

5.17 ± 1.59

5.82 ± 1.19

4.74 ± 1.66

0.045

d-Dimer (ug/mL FEU)

3.63 ± 5.42

4.30 ± 6.65

3.18 ± 4.54

0.556

 > 1.0 ug/mL FEU

21

8

13

0.778

 ≤ 1.0 ug/mL FEU

14

6

8

 

NT-pro-BNP (ug/mL)

253.20 ± 346.51

318.29 ± 520.19

209.81 ± 152.60

0.372

cTnI (pg/mL)

9.11 ± 9.51

8.43 ± 9.38

9.56 ± 9.79

0.736

ESR (mm/h) (/n)

47.75 ± 26.74 (32)

58.62 ± 19.90 (13)

40.32 ± 28.70 (19)

0.056

hsCRP (mg/L)

33.89 ± 38.61

31.47 ± 24.06

35.50 ± 46.39

0.767

Procalcitonin (ng/mL)

0.17 ± 0.46

0.10 ± 0.08

0.21 ± 0.60

0.507

 ≥ 0.1 ng/mL

9

5

4

0.432

 < 0.1 ng/mL

26

9

17

 

Ferritin (ug/L) (n)

819.36 ± 628.02 (31)

689.45 ± 494.53 (13)

913.18 ± 707.92 (18)

0.336

IL-6 (ug/mL) (n)

14.49 ± 15.62 (31)

13.28 ± 9.27 (13)

15.37 ± 19.19 (18)

0.721

Other respiratory pathogen infectionc

21

10

11

0.260

Imaging findings

    

 GGO

30

14

16

0.069

 Consolidation

19

7

12

0.678

 Bilateral pulmonary infiltration

34

14

20

1.000

 Interstitial changes

17

7

10

0.890

 Hydrothorax

7

1

6

0.203

  1. HBV hepatitis B virus, WBC white blood cell, Neu neutrophil, Lym lymphocyte, Hb hemoglobulin, PLT platelet, ALT alanine transaminase, AST oxaloacetic transaminase, LDH lactate dehydrogenase, eGFR estimated glomerular filter rate, NT-pro-BNP N-terminal pro-Brain Natriuretic Peptide, cTnI cardiac troponin I, ESR erythrocyte sedimentation rate, hsCRP high sensitivity C reactive protein, IL-6 interleukin-6, GGO ground glass opacity, HCQ hydroxychloroquine, CQ chloroquine
  2. aIncluding carcinoma in the stomach (n = 2), urinary bladder (n = 1), bone (n = 1) and breast (n = 1)
  3. bLung disease refers to chronic obstructive lung disease (n = 3), emphysema (n = 2), bronchiectasis (n = 1), lung fibrosis (n = 1) and bullae (n = 1)
  4. cOther concurrent respiratory pathogen infection with a specific serum immunoglobulin M positive confirmed by the enzyme-linked immunosorbent assay includes type A influenza (n = 18), type B influenza (n = 2), mycoplasma pneumoniae (n = 2) and chlamydia pneumoniae (n = 1)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us